Bristol-Myers Squibb Company (BMY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $129.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bristol-Myers Squibb Company (BMY) P/E Ratio & Valuation History
Bristol-Myers Squibb Company (BMY) trades at 10.1x trailing earnings and 2.6x sales. Its P/E of 10.1x is above its 5-year median of 9.2x. Its forward P/E is 9.6x. The median P/E across 9 similar companies is 21.4x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 5.2% higher over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 10.1x |
| Forward P/E | 9.6x |
| Price to sales | 2.6x |
| Price to book | 5.5x |
| EV/EBITDA | 11.5x |
| Price to FCF | 13.9x |
| EV/FCF | 17.4x |
| PEG | N/A |
| FCF yield | 7.2% |
Historical Medians
Against its 10-year medians, its P/E is 1.0% below 10.2x, its P/S is 21.2% below 3.3x and its P/B is 5.8% above 5.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 10.1x | 9.2x | 10.2x |
| P/S | 2.6x | 2.5x | 3.3x |
| P/B | 5.5x | 5.1x | 5.2x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 6.9x in 2023 to 49.6x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $53.94 | 8.8x | 2.3x | 6.0x |
| 2024 | $56.56 | 49.6x | 2.4x | 7.1x |
| 2023 | $51.31 | 6.9x | 2.4x | 3.5x |
| 2022 | $71.95 | 9.3x | 3.3x | 4.9x |
| 2021 | $62.35 | 8.3x | 3.0x | 3.8x |
| 2020 | $62.03 | 9.6x | 3.7x | 3.7x |
| 2019 | $64.19 | 13.7x | 4.2x | 2.4x |
| 2018 | $51.98 | 13.1x | 3.8x | 6.1x |
| 2017 | $61.28 | 20.4x | 4.8x | 8.6x |
| 2016 | $58.44 | 20.7x | 5.0x | 6.1x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BMY
What is BMY's forward P/E ratio?
Bristol-Myers Squibb Company has a forward P/E ratio of 9.6x.
Is BMY stock overvalued?
GNG's valuation label for BMY is Fairly valued. Its P/E of 10.1x compares with a median of 21.4x across 9 similar companies.
What is BMY's price to sales ratio?
Bristol-Myers Squibb Company has a price to sales ratio of 2.6x.
What is Bristol-Myers Squibb Company's average P/E ratio over 5 years?
Bristol-Myers Squibb Company's median P/E over the last 5 years is 9.2x, from 60 month-end values through Oct 2026.
BMY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts